Litcius/Paper detail

Reactive T Cells in Convalescent COVID-19 Patients With Negative SARS-CoV-2 Antibody Serology

Sophie Steiner, Tatjana Schwarz, Victor M. Corman, Franziska Sotzny, Sandra Bauer, Christian Drosten, Hans‐Dieter Volk, Carmen Scheibenbogen, Leif G. Hanitsch

2021Frontiers in Immunology32 citationsDOIOpen Access PDF

Abstract

Despite RT-PCR confirmed COVID-19, specific antibodies to SARS-CoV-2 spike are undetectable in serum in approximately 10% of convalescent patients after mild disease course. This raises the question of induction and persistence of SARS-CoV-2-reactive T cells in these convalescent individuals. Using flow cytometry, we assessed specific SARS-CoV-2 and human endemic coronaviruses (HCoV-229E, -OC43) reactive T cells after stimulation with spike and nucleocapsid peptide pools and analyzed cytokine polyfunctionality (IFN γ , TNFα, and IL-2) in seropositive and seronegative convalescent COVID-19 patients as well as in unexposed healthy controls. Stimulation with SARS-CoV-2 spike and nucleocapsid (NCAP) as well as HCoV spike peptide pools elicited a similar T cell response in seropositive and seronegative post COVID-19 patients. Significantly higher frequencies of polyfunctional cytokine nucleocapsid reactive CD4+ T cells (triple positive for IFN γ , TNFα, and IL-2) were observed in both, seropositive (p = 0.008) and seronegative (p = 0.04), COVID-19 convalescent compared to healthy controls and were detectable up to day 162 post RT-PCR positivity in seronegative convalescents. Our data indicate an important role of NCAP-specific T cells for viral control.

Topics & Concepts

SerologyVirologyAntibodyImmunologyCytokineCoronavirusFlow cytometryMedicineCoronavirus disease 2019 (COVID-19)BiologyDiseaseInternal medicineInfectious disease (medical specialty)SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesLong-Term Effects of COVID-19
Reactive T Cells in Convalescent COVID-19 Patients With Negative SARS-CoV-2 Antibody Serology | Litcius